Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer: Ancillary Study to SWOG-9252 (INT-0115, E3590, RTOG-91-05, NCCTG 91-24-51)

Closed

Phase

Published

Abbreviated Title

Activated

03/01/1994

Closed

12/01/1996

Research committees

Lung Cancer

Publication Information Expand/Collapse

2001

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a lab ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postop adjuvant therapy

JH Schiller;S Adak;RH Feins;SM Keller;WA Fry;RB Livingston;MEM Hammond;B Wolf;L Sabatini;J Jett;L Kohman;DH Johnson Journal of Clinical Oncology 19(2):448-457

1999

Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: Preliminary results from a propsective randomized trial of postoperative adjuvant therapy (intergroup trial 0115).

JH Schiller;S Adak;R Feins;S Keller;W Fry;RB Livingston;B Wolf;J Jett;L Kohman;D Johnson;E Hammond Proc of the American Society of Clinical Oncology 18:464a(#1789)

Other Clinical Trials

SWOG Clinical Trial Number

S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER

Research Committee(s)

Lung Cancer

Activated

03/06/2023

Accrual

86%

Open

Phase

SWOG Clinical Trial Number

A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Research Committee(s)

Lung Cancer

Activated

12/21/2021

Open

Phase

SWOG Clinical Trial Number

CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Research Committee(s)

Lung Cancer

Activated

08/17/2020

Open